Comparative effectiveness research using electronic health records: Impacts of oral antidiabetic drugs on the development of chronic kidney disease

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 4, 2013, Pages 413-422

  Masica, Andrew ^a   Ewen, Edward ^b   Daoud, Yahya ^a   Cheng, Dunlei ^f   Franceschini, Nora ^e   Kudyakov, Rustam ^a   Bowen, James ^b   Brouwer, Emily S ^d   Wallace, Dennis ^c   Fleming, Neil ^a   West, Suzanne L ^c,e  

^a BAYLOR HEALTH CARE SYSTEM   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

^c RTI INTERNATIONAL   (United States)

^d University of Kentucky   (United States)

^e University of North Carolina at Chapel Hill   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Chronic kidney disease; Comparative effectiveness; Diabetes; Electronic health record; Oral antidiabetic drugs; Pharmacoepidemiology

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGED; COHORT STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84875812096     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3413     Document Type: Article

References (32)

1. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008; 31: 596-615.
2. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med 1989; 111: 788-796.
3. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases; 2007.
4. Palumbo PJ, Elveback LR, Chu CP, Connolly DC, Kurland LT. Diabetes mellitus: incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945-1970. Diabetes 1976; 25: 566-573.
5. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613.
6. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
9. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076.
10. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000; 14: 250-254.
11. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008; 19: 182-187.
12. Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012; 81: 698-706.
13. Agency for Healthcare Research and Quality. Effective Health Care Program: About the DEcIDE Network. http://www.effectivehealthcare.ahrq.gov/index.cfm/who-is-involved-in-the-effective-health-care-program1/about-the-decide-network/ (accessed September 20, 2010).
14. Nathan DM. Time for clinically relevant comparative effectiveness studies in type 2 diabetes. Ann Intern Med 2011; 154: 131-132.
15. Cebul RD, Love TE, Jain AK, Hebert CJ. Electronic health records and quality of diabetes care. N Engl J Med 2011; 365: 825-833.
16. Kudyakov R, Ewen E, West S, et al. Electronic health record use to classify patients with newly diagnosed versus pre-existing type 2 diabetes: infrastructure for comparative effectiveness and population health management. Popul Health Manag 2012; 15: 3-11.
17. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
18. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
19. Zhou XH, Obuchowski NA, McClish DK. Statistical Methods in Diagnostic Medicine. Wiley: New York; 2002.
20. Little R, Rubin D. Statistical Analysis with Missing Data (2nd edn), Wiley: New York, 2002.
21. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007; 45: S103-S107.
22. Kramer JM, Curtis LH, Dupree CS, et al. Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med 2008; 168: 2422-2428.
23. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168: 656-664.
24. Agrawal S, Guess AJ, Benndorf R, Smoyer WE. Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects. Mol Pharmacol 2011; 80: 389-99.
25. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151(1-10): W11-W12.
26. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
27. Burgess E. Reviewing the benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy--are they drug specific or class specific? Can J Cardiol 2010; 26: 15E-19E.
28. American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34: S11-S61.
29. Vlassara H, Torreggiani M, Post JB, Zheng F, Uribarri J, Striker GE. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl 2009; 76: S3-S11.
30. Skrha J, Prazny M, Hilgertova J, Kvasnicka J, Kalousová M, Zima T. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol 2007; 63: 1107-1114.
31. Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart WF. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med 2008; 24: 233-7.
32. Raebel MA, Carroll NM, Ellis JL, Schroeder EB, Bayliss EA. Importance of including early nonadherence in estimations of medication adherence. Ann Pharmacother 2011; 45: 1053-60.